Cervical cancer overview and latest developments
The NHS has announced a phased rollout of free self-testing kits for cervical cancer screening, sent by invite or via NHS app to eligible women. The program aims to boost screening uptake and move toward eliminating cervical cancer by 2040. Health officials highlight that home testing is discreet, convenient and can detect high‑risk HPV; positives lead to clinician follow‑ups.
A QMUL-led Lancet study shows the HPV vaccine has dramatically reduced cervical cancer deaths among 20-24-year-olds in England from 2020–2024. England also sees an 80% fall in deaths in 2015–2019 for this age group. Yet uptake gaps threaten future gains as vaccination rates fall in parts of the country.
A round-up of recent cancer-related reports shows patients benefiting from clinical trials and rare misdiagnoses being corrected. From rectal cancer trials in the UK to cervical cancer misdiagnoses under review, readers are kept informed on treatment advances and patient experiences.
An international trial shows weekly HIV medication is as effective as daily doses, potentially reducing stigma and treatment burden. In Ghana, authorities reassure continued ARV availability amid distribution concerns. Nigerian and Ugandan health updates highlight high suppression rates and ongoing prevention efforts.
Moderna has reported that its mRNA-based cancer vaccine, tested with Merck’s Keytruda, has prevented recurrence in a melanoma trial and shown a clinically meaningful improvement over immunotherapy alone. The findings could signal a shift toward personalized cancer vaccines, with a potential launch next year amid investor optimism.
A long-term study has found that men with cardiovascular disease have a higher lifetime cancer risk (17.3%) than women (12.8%), with smoking, obesity and alcohol as primary drivers. The risk is elevated for several cancers, notably gastric, oesophageal and lung cancer, and deaths are higher in men with heart disease. Researchers call for improved risk management and targeted screening.